Introduction
============

Lung cancer contributes significantly to cancer-related mortality and is a major public health burden in the world [@B1]. In China alone, the incidence and mortality associated with lung cancer are estimated to be 0.7 and 0.6 million cases, respectively [@B2]. To date, most lung cancer patients are diagnosed at an advanced stage with a 5-year survival rate of approximately 15%, whereas the 5-year survival rate of early stage lung cancer patients is 30-40%. Thus, early detection and effective treatment could markedly improve patient survival [@B3]. Pathologically, genetic and environmental interactions play a key role in the development of lung cancer [@B4]. However, these interactions are dependent of genetic variations or single nucleotide polymorphisms (SNPs). Therefore, identifying specific SNPs associated with an increased risk of developing lung cancer could reduce lung cancer incidence.

The proto-oncogene Wnt-1 belongs to the WNT family of structurally related genes that encode secreted signaling proteins. Functionally, these proteins have been implicated in both tumorigenesis and embryonic development, including cell fate and patterning [@B5]-[@B11]. The Wnt co-receptor, low-density lipoprotein receptor-related protein 6 (LRP6), plays a dominant role in Wnt signal transduction [@B12]. LRP6, a member of the LRP superfamily, is required for activation of the canonical Wnt signaling pathway. Structurally, human LRP6 protein has a large extracellular domain containing four β-propeller-plus EGF repeats, which are essential for binding to Wnt, various ligands and antagonists, and three LDLR-A repeats [@B13]-[@B14]. Aberrant LRP6 expression alters Wnt ligand binding and receptor activation, and extracellular antagonists are associated with stem cell self-renewal and differentiation as well as cancer development and progression [@B15]. Specifically, LRP6 protein binding to the Frizzled family member, leads to the activation of the Wnt pathway [@B16] and the subsequent stabilization and nuclear translocation of β-catenin [@B17]. Pharmacological inhibition of the LRP6 Wnt-binding domains leads to the suppression of the Wnt pathway and its downstream gene regulatory mechanisms [@B18]. In this study, we hypothesized that *LRP6* polymorphisms could play a role in the susceptibility of non-small cell lung cancer (NSCLC). Specifically, we assessed four different *LRP6* SNPs in a case and control study to determine their association with the risk of developing NSCLC.

Patients and Methods
====================

Study population
----------------

In this study, we recruited 500 NSCLC patients and 500 unrelated age-matched healthy controls from The Zhejiang Cancer Hospital, Hangzhou, China between March, 2011 and April, 2012. All subjects were of Han origin and lived roughly within the same geographic region (Zhejiang Province, China). Patients with a prior history of primary cancer, other than lung cancer, were excluded from this study. To avoid any probable interference from overlapping genes, the controls did not have any lung-related diseases. A tobacco smoker was defined as one who had smoked more than ten packs of tobacco in their life time, and a current or former smoker was defined as a smoker who was still smoking in the current year or in a year before participation of this study [@B20]. This study was approved by the ethics committee of Zhejiang Cancer Hospital. All subjects included in this study provided informed consent before participation.

SNPs selection and genotyping
-----------------------------

Four *LRP6* SNPs, with a pairwise r^2^≥ 0.8 and minor allele frequency (MAF) ≥ 0.15, were selected by searching the SNP Browser (version 3.5) and the Tagger program implemented in Haploview version 4.1 (<http://www.broad.mit.edu/mpg/haploview>).

We extracted genomic DNA from whole blood using the AxyPrep Blood Genomic DNA Miniprep kit (Axygen Biosciences, Union City, CA). The four *LRP6* SNPs of interest were then genotyped using the SEQUENOM MassARRAY matrix-assisted laser desorption ionization-time of flight mass spectrometry platform (Sequenom, San Diego, CA). PCR primers and single base extension primers were designed using Assay Designer\'s software version 3.0 (Sequenom) and synthesized by Sangon Biotech (Shanghai, China) (Table [1](#T1){ref-type="table"}).

Statistical analysis
--------------------

All statistical analyses were performed using SPSS 13.0 for Windows (SPSS Inc., Chicago, IL). Hardy-Weinberg equilibrium (HWE) was carried out between cases and control for all SNPs using the χ^2^ test. A *P*\<0.001 was considered discrepant. The χ^2^ test was also used to assess the frequencies of the selected alleles and genotypes. The association between SNPs and NSCLC risk and the link between tobacco smoke and NSCLC risk were evaluated by computing the odds ratio (OR) and 95% confidence interval (CI) with multivariate unconditional logistic regression analyses. A two-sided P\<0.05 was considered statistically significant.

Results
=======

Clinical characteristics of the study population
------------------------------------------------

Of the 500 NSCLC patients, 350 were male and 150 were female, and 331 patients were diagnosed with adenocarcinoma (ADC), while 169 had squamous-cell carcinomas (SCC). In addition, 280 male and 21 female patients were current or former smokers. There were 500 age-matched healthy controls (259 male and 240 female, and one subject did not have gender information). In the control group, 189 male and 14 female control subjects were current or former smokers. All subjects included in this study were of Chinese Han origin.

For all of the *LRP6* SNPs (rs10845498, rs2075241, rs6488507, and rs7136900), cases and controls were within HWE (*p* = 0.87, 0.29, 0.30 and 0.26 for the cases; p=0.31, 0.47, 0.75 and 0.67 for controls, respectively).

LRP6 polymorphisms between case and control
-------------------------------------------

The allele frequency of *LRP6* rs10845498 was 80.2% (A) and 19.8% (G) in NSCLC patients, 81.0% (A) and 19.0% (G) in ADC patients, 78.7% (A) and 21.3% (G) in SCC patients, and 82.8% (A) and 17.2% (G) in controls. Allele frequency of *LRP6* rs2075241 was 9.6% (C) and 90.4% (G) in NSCLC patients, 10.7% (C) and 89.3% (G) in ADC patients, 12.4% (C) and 87.6% (G) in SCC patients, and 9.6% (C) and 90.4% (G) in controls. Allele frequency of *LRP6* rs6488507 was 24.2% (A) and 75.8% (G) in NSCLC patients, 25.8% (A) and 74.2% (G) in ADC patients, 26.0% (A) and 74.0% (G) in SCC patients, and 25.9% (A) and 74.1% (G) in controls. No statistical differences in allele frequencies of these four SNPs were found between the case and control subjects (p\> 0.05). Stratification by gender revealed no significant difference in allele frequencies between male patients and male controls and between female patients and female controls (Table [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, and [4](#T4){ref-type="table"}).

*LRP6* genotype distributions were also analyzed. Specifically, the frequency of the *LRP6* rs10845498 genotype was 64.2% for A/A, 32.0% for A/G, and 3.8% for G/G in NSCLC patients, 69.2% for A/A, 27.2% for A/G, and 3.6% for G/G in the controls. In contrast the frequency was 65.9% for A/A, 30.2% for A/G, and 3.9% for G/G in ADC patients and 60.9% for A/A, 35.5% for A/G, and 3.6% for G/G in SCC patients. There was no statistical difference of these four *LRP6* SNP genotypes between NSLCLCs and controls, between ADC and controls, and between SCC and controls. After stratifying by gender, no statistical difference was observed. However, the *LRP6* rs10845498 A/A major allele homozygote was associated with a decreased risk of lung SCC (OR = 0.69; 95% CI, 0.48-1.00; Table [5](#T5){ref-type="table"}).

Association between tobacco smoke and NSCLC
-------------------------------------------

We also analyzed the association of tobacco smoke with NSCLC risk. Logistic regression analysis showed that tobacco smokers had a 2.21-fold greater risk in developing NSCLC than nonsmokers (*p \< 0.01,* 95%CI, 1.72-2.85). Moreover, we found that the *LRP6* rs6488507 polymorphism synergistically increased the risk of NSCLC in tobacco smokers. For example, tobacco smokers who carried an "A" allele (AA+AG) had a 2.34-fold greater risk in developing NSCLC than other patients (*p\< 0.01,* 95%CI, 1.74-3.13).

Discussion
==========

In the current study, we investigated the association between *LRP6*SNPs and the risk of developing NSCLC. Indeed, we found that the *LRP6*rs10845498 polymorphism was associated with a reduced risk of lung SCC and that the *LRP6* rs6488507 polymorphism synergistically increased the risk of NSCLC in tobacco smokers. To the best of our knowledge, this is the first report to demonstrate an association of the *LRP6*rs10845498 SNP with NSCLC risk. However, further investigation is needed to elucidate mechanistic links between the*LRP6*rs10845498 SNP, changes in LRP6 protein expression and activity, and lung cancer development and progression.

*LRP6* is localized on chromosome 12p13.2, which is frequently deleted in NSCLC tissues [@B22]-[@B23]. The imbalance of chromosomal 12p is also associated with disease progression [@B24]. In addition, chromosomal 12p gain-of-function is also closely associated with tumorigenesis and/or the progression of lung SCC [@B25]. LRP6 is an essential co-receptor for Wnt/β-catenin signaling [@B26]-[@B27] and plays a role in multiple processes involved in lung cancer development [@B28]. One study demonstrated a novel lung metastasis signature linked to Wnt signaling in basal-like breast cancer. Inhibition of Wnt signaling via LRP6 reduced the capacity of cancer cells to self-renew and seed tumors *in vivo* [@B29]. In accordance with these studies, our study indicated LRP6 may a susceptibility gene involved in NSCLC development. In this study, the *LRP6* rs10845498 polymorphism was inversely associated with the development of lung SCC in a Chinese population. A/A homozygote individuals had a 0.69-fold reduced risk in developing NSCLC compared to G/G homozygote or A/G heterozygote individuals. In addition we found that tobacco smokers had a 2.21-fold greater risk in developing NSCLC, while the *LRP6* rs6488507 polymorphism synergistically increased the risk of lung cancer risk in tobacco smokers. Interestingly, the *LRP6* rs6488507 polymorphism itself was not associated with the risk of developing NSCLC. However, since the MAF of SNPs varies significantly between populations, associations based on these SNPs will be particularly sensitive to ethnic variability. Indeed, analysis of the HapMap database revealed a significant variability in the MAF of the *LRP6* rs10845498 SNP among different populations. Specifically, the MAF of the *LRP6* rs10845498 SNP in European (0.18) and Asian (0.21) populations is low, while it is high in Sub-Saharan African (0.29). Thus, the findings of the current study may be limited to Chinese patients and possibly other Asian populations. Indeed, further investigation is needed to confirm the applicability of our findings to other patient populations.

In the current study, the *LRP6* rs10845498 polymorphism was associated with NSCLC risk, as well as synergistically affected NSCLC risk in tobacco smokers. However, our current study has some limitations. For example, we did not obtain clinicopathological data from the patients. In addition, our sample size was relatively small, which may have affected the result. In addition, population stratification may have led to a bias because the frequency of genotypes for many polymorphic variants differs markedly among different ethnic groups.

###### 

PCR primers and extension used in genotyping of LRP6 SNPs.

  SNP          Primers     Sequences
  ------------ ----------- --------------------------------
  Rs10845498   1           ACGTTGGATGGAGAGGACTGTTAAAGCTGG
               2           ACGTTGGATGTGTGTGGTTAATGTGGGAGG
               Extension   CCCCTGGAGAGTAGGGGAGAGAGAG
  Rs2075241    1           ACGTTGGATGCACAGGCTGCAAGATATTGG
               2           ACGTTGGATGTGACCCACATGAGTCATTTC
               Extension   GAACTGAGTCATTTCTGTTGAATTTTCT
  Rs6488507    1           ACGTTGGATGGTTAATAAGTAATCTGTGGG
               2           ACGTTGGATGCAAGGATTCAAAAACCACTG
               Extension   AAAGGATATTTACACCATTTCA
  Rs7136900    1           ACGTTGGATGACAGTTGTATGCCACTGTGC
               2           ACGTTGGATGAAGCTTACAGCCTAGTTTGG
               Extension   GAAGGCCTAGTTTGGAAACACT

###### 

Allele frequency of *LRP6* SNPs in NSCLC patients and healthy controls.

  Gene allele      NSCLC Controls   p value      OR(95% CI)   M NSCLC            M Controls   p value      OR (95% CI)   F NSCLC            F Controls   p value      OR(95% CI)   
  ---------------- ---------------- ------------ ------------ ------------------ ------------ ------------ ------------- ------------------ ------------ ------------ ------------ ------------------
                   N=500 (%)        N=500 (%)                                    N=350 (%)    N=259 (%)                                     N=150 (%)    N=240 (%)                 
  **Rs10845498**                                                                                                                                                                   
  A                802 (80.2)       828 (82.8)                                   559 (79.9)   424 (81.9)                                    243 (81.0)   403 (84.0)                
  G                198 (19.8)       172 (17.2)   0.13         0.84 (0.67-1.06)   141 (20.1)   94 (18.1)    0.38          0.88 (0.66-1.18)   57 (19.0)    77 (16.0)    0.29         0.81 (0.55-1.19)
  **Rs2075241**                                                                                                                                                                    
  C                96 (9.6)         113 (11.3)                                   80 (11.4)    57 (11.0)                                     33 (11.0)    39 (8.1)                  
  G                904 (90.4)       887 (88.7)   0.21         1.20 (0.90-1.60)   620 (88.6)   461 (89.0)   0.82          1.04 (0.73-1.50)   267 (89.0)   441 (91.9)   0.19         1.39 (0.84-2.28)
  **Rs 6488507**                                                                                                                                                                   
  A                242 (24.2)       259 (25.9)                                   184 (26.3)   129 (24.9)                                    75 (25.0)    111 (23.1)                
  G                758 (75.8)       741 (74.1)   0.38         1.09 (0.89-1.34)   516 (73.7)   389 (75.1)   0.58          1.08 (0.83-1.39)   225 (75.0)   369 (76.9)   0.55         1.11 (0.79-1.55)
  **Rs7136900**                                                                                                                                                                    
  A                69 (6.9)         81 (8.1)                                     51 (7.3)     35 (6.8)                                      18 (6.0)     45 (9.4)                  
  G                931 (93.1)       919 (91.9)   0.31         0.84 (0.60-1.17)   649 (92.7)   483 (93.2)   0.72          1.08 (0.69-1.69)   282 (94.0)   435 (90.6)   0.09         0.62 (0.35-1.09)

NSCLC, Non-small cell lung cancer; M, Male; F, Female.

###### 

Allele frequency of *LRP6* SNPs in ADC patients and controls.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene allele   ADC          Controls     p value   OR (95% CI)        M ADC        M Controls   p value   OR\                F ADC        F Controls   p value   OR(95% CI)         
                                                                                                           (95% CI)                                                                  
  ------------- ------------ ------------ --------- ------------------ ------------ ------------ --------- ------------------ ------------ ------------ --------- ------------------ --
                N=331 (%)    N=500 (%)                                 N=189 (%)    N=259 (%)                                 N=142 (%)    N=240 (%)                                 

  Rs10845498                                                                                                                                                                         

  A             536 (81.0)   828 (82.8)                                306 (81.0)   424 (81.9)                                230 (81.0)   403 (84.0)                                

  G             126 (19.0)   172 (17.2)   0.34      0.88 (0.69-1.14)   72 (19.0)    94 (18.1)    0.38      0.88 (0.66-1.18)   54 (19.0)    77 (16.0)    0.29      0.81 (0.55-1.19)   

  Rs2075241                                                                                                                                                                          

  C             71 (10.7)    96 (9.6)                                  40 (10.6)    57 (11.0)                                 31 (10.9)    39 (8.1)                                  

  G             591 (89.3)   904 (90.4)   0.46      1.13 (0.82-1.56)   338 (89.4)   461 (89.0)   0.84      0.96 (0.62-1.47)   253 (89.1)   441 (91.9)   0.19      1.39 (0.84-2.28)   

  Rs 6488507                                                                                                                                                                         

  A             171 (25.8)   242 (24.2)                                99 (26.2)    129 (24.9)                                72 (25.4)    111 (23.1)                                

  G             491 (74.2)   758 (75.8)   0.45      1.09 (0.87-1.37)   279 (73.8)   389 (75.1)   0.66      1.07 (0.79-1.45)   212 (74.6)   369 (76.9)   0.49      1.13 (0.80-1.59)   

  Rs7136900                                                                                                                                                                          

  A             46 (6.9)     81 (8.1)                                  28 (7.4)     35 (6.8)                                  18 (6.3)     45 (9.4)                                  

  G             616 (93.1)   919 (91.9)   0.39      0.85 (0.58-1.23)   350 (92.6)   483 (93.2)   0.71      1.10 (0.66-1.85)   266 (93.7)   435 (90.6)   0.14      0.65 (0.37-1.15)   

                                                                                                                                                                                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADC, adenocarcinoma; M, Male; F, Female.

###### 

Allele frequency of *LRP6* SNPs in SCC patients and controls.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene allele      SCC          Controls     p value   OR\                M SCC        M Controls   p value   OR\                F SCC       F Controls   p value   OR\
                                                       (95% CI)                                               (95% CI)                                              (95% CI)
  ---------------- ------------ ------------ --------- ------------------ ------------ ------------ --------- ------------------ ----------- ------------ --------- ------------------
                   N=169 (%)    N=500 (%)                                 N=161 (%)    N=259(%)                                  N=8 (%)     N=240 (%)              

  **Rs10845498**                                                                                                                                                    

  A                266 (78.7)   828 (82.8)                                253 (78.6)   424 (81.9)                                13 (81.3)   403 (84.0)             

  G                72 (21.3)    172 (17.2)   0.09      0.77 (0.56-1.04)   69 (21.4)    94 (18.1)    0.24      0.81 (0.57-1.15)   3 (18.7)    77 (16.0)    0.77      0.83 (0.23-2.97)

  **Rs2075241**                                                                                                                                                     

  C                42 (12.4)    96 (9.6)                                  40 (12.4)    57 (11.0)                                 2 (12.5)    39 (8.1)               

  G                296 (87.6)   904 (90.4)   0.14      1.33 (0.91-1.97)   282 (87.6)   461 (89.0)   0.53      1.15 (0.75-1.77)   14 (87.5)   441 (91.9)   0.53      1.62 (0.35-7.37)

  **Rs 6488507**                                                                                                                                                    

  A                88 (26.0)    242 (24.2)                                85 (26.4)    129 (24.9)                                3 (18.8)    111 (23.1)             

  G                250 (74.0)   758 (75.8)   0.50      1.10 (0.83-1.46)   237 (73.6)   389 (75.1)   0.63      1.08 (0.79-1.49)   13 (81.3)   369 (76.9)   0.68      0.77 (0.22-2.74)

  **Rs7136900**                                                                                                                                                     

  A                23 (6.8)     81 (8.1)                                  23 (7.1)     35 (6.8)                                  0 (0.0)     45 (9.4)               

  G                315 (93.2)   919 (91.9)   0.44      0.83 (0.51-1.34)   299 (92.9)   483 (93.2)   0.83      1.06 (0.62-1.83)   16 (1.0)    435 (90.6)   0.20      \-
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SCC, squamous cell carcinoma; M, Male; F, Female.

###### 

Genotypes of *LRP6* SNPs in SCC patients and controls.

  Gene allele   SCC          Controls     p value    OR(95% CI)             M SCC        M Controls   p value   OR (95% CI)        F SCC      F Controls   p value   OR(95% CI)
  ------------- ------------ ------------ ---------- ---------------------- ------------ ------------ --------- ------------------ ---------- ------------ --------- ------------------
                N=169 (%)    N=500 (%)                                      N=161n(%)    N=259 (%)                                 N=8 (%)    N=240 (%)              
  Rs10845498                                                                                                                                                         
  AA            103 (60.9)   346 (69.2)                                     97 (60.2)    178 (68.7)                                6 (75.0)   168 (70.0)             
  AG            60 (35.5)    136 (27.2)                                     59 (36.6)    68 (26.3)                                 1 (12.5)   67 (27.9)              
  GG            6 (3.6)      18 (3.6)     0.12                              5 (3.1)      13 (5.0)     0.06                         1 (12.5)   5 (2.1)      0.12      
  AG+GG         66 (39.1)    154 (30.8)   **0.04**   **0.69 (0.48-1.00)**   64 (39.8)    81 (31.3)    0.08      0.69 (0.46-1.04)   2 (25.0)   72 (30.0)    0.76      1.29 (0.25-6.52)
  Rs2075241                                                                                                                                                          
  GG            127 (751)    410 (82.0)                                     121 (75.2)   205 (79.2)                                6 (75.0)   204 (85.0)             
  CG            42 (249)     84 (16.8)                                      40 (24.8)    51 (19.7)                                 2 (25.0)   33 (13.8)              
  CC            0 (0.0)      6 (1.2)      0.03                              0 (0.0)      3 (1.2)      0.19                         0 (0.0)    3 (1.3)      0.64      
  CC+CG         42 (24.9)    90 (18.0)    0.05       0.66 (0.44-1.01)       40 (24.8)    54 (20.8)    0.34      0.80 (0.50-1.27)   2 (25.0)   36 (15.0)    0.44      0.53 (0.10-2.73)
  Rs6488507                                                                                                                                                          
  GG            92 (54.4)    286 (57.2)                                     86 (53.4)    148 (57.1)                                6 (75.0)   138 (57.5)             
  AG            66 (39.1)    186 (37.2)                                     65 (40.4)    93 (35.9)                                 1 (12.5)   9 (3.7)                
  AA            11 (6.5)     28 (5.6)     0.79                              10 (6.2)     18 (6.9)     0.65                         1 (12.5)   93 (38.8)    0.19      
  AA+AG         77 (45.6)    214 (42.8)   0.53       1.12 (0.79-1.59)       75 (46.6)    111 (42.9)   0.45      1.16 (0.78-1.73)   2 (25.0)   102 (42.5)   0.32      0.45 (0.09-2.28)
  Rs7136900                                                                                                                                                          
  GG            147 (87.0)   423 (84.6)                                     139 (86.3)   226 (87.3)                                8 (1.0)    197 (82.1)             
  AG            21 (12.4)    73 (14.6)                                      21 (13.0)    31 (12.0)                                 0 (0.0)    41 (17.1)              
  AA            1 (0.6)      4 (0.8)      0.75                              1 (0.6)      2 (0.8)      0.94                         0 (0.0)    2 (0.8)      0.42      
  AG+AA         22 (13.0)    77 (15.4)    0.45       0.82 (0.49-1.37)       22 (13.7)    33 (12.7)    0.78      1.08 (0.61-1.94)   0 (0.0)    43 (17.9)    0.19      \-

SCC, squamous cell carcinoma; M, Male; F, Female.
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